REZIRA ORAL SOLUTION CII
Generic Name and Formulations:
Hydrocodone bitartrate 5mg, pseudoephedrine hydrochloride 60mg; per 5mL; grape-flavor.
Indications for REZIRA ORAL SOLUTION:
Cough and nasal congestion associated with common cold.
Use accurate measuring device. ≥18yrs: 5mL every 4–6hrs as needed. Max: 4 doses (20mL) per 24hrs.
<18yrs: not established.
During or within 14 days of MAOIs. Narrow angle glaucoma. Urinary retention. Severe hypertension. Severe coronary artery disease.
Risks from concomitant benzodiazepines or other CNS depressants (see Interactions). Discontinue if respiratory depression occurs. Abuse potential (monitor). Avoid in head injury, other intracranial lesions or pre-existing increase in intracranial pressure. Acute abdomen. Cardiovascular disorders. Diabetes. Thyroid disorders. Addison's disease. Prostatic hypertrophy. Urethral stricture. Asthma. Severe hepatic or renal impairment. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Increased risk of respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, opioids, antihistamines, antipsychotics, anxiolytics, alcohol); avoid. Hypertensive crisis with MAOIs. May affect or be affected by TCAs. Paralytic ileus may occur with anticholinergics.
Antitussive + sympathomimetic.
Sedation, drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, dizziness, psychic dependence, mood changes, nervousness or sleeplessness, tremor, arrhythmia; respiratory depression, cardiovascular effects.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma